"It was just a discussion over a glass of beer in Geneva, and I said, 'Okay, we'll do it.'"
The Serum Institute of India became the first company to re-license a vaccine for use outside of the cold chain - the cold chain is a method of constant refrigeration that is required for most vaccines to keep their potency but which is completely unrealistic for many rural areas in developing countries.
The Meningitis A vaccine can now be kept outside of refrigeration at temperatures up to 104 F (40C) for up to 4 days. As a result, many more children will have access to this life-saving vaccine. So what incentives do pharmaceutical companies need to produce more better adapted vaccines for developing countries?